lopinavir and HIV
lopinavir has been researched along with HIV in 76 studies
*HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. [MeSH]
Research
Studies (76)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (43.42) | 29.6817 |
| 2010's | 34 (44.74) | 24.3611 |
| 2020's | 9 (11.84) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Betebenner, DA; Herrin, T; Kempf, DJ; Kumar, G; Molla, A; Norbeck, DW; Plattner, JJ; Saldivar, A; Sham, HL; Vasavanonda, S | 1 |
| Brieger, M; Furfine, ES; Hazen, RJ; Kaldor, I; Miller, JF; Reynolds, D; Sherrill, RG; Spaltenstein, A | 1 |
| Arvidsson, PI; Govender, P; Govender, T; Honarparvar, B; Kruger, HG; Maguire, GE; Makatini, MM; Petzold, K; Sayed, Y; Soliman, ME; Sriharsha, SN | 1 |
| Aidara, M; Alleyo, A; Diallo, K; Manga, NM; Wembulua, BS | 1 |
| Jacobs, BA; Mtshali, S | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H | 1 |
| George, PE; Mercedes, R; Nabukeera-Barungi, N; Otto, SBJ | 1 |
| Cao, Y; Xu, S; Zhou, M; Zhu, F | 1 |
| Alonso-Castro, AJ; Alvarez-Alvarez, RM; Del Carmen Preciado-Puga, M; Del Rocio Ibarra-Reynoso, L; Lazo-de-la-Vega-Monroy, ML; Ruiz-Noa, Y; Ruiz-Padilla, AJ; Sánchez-Barajas, M | 1 |
| Agolory, S; Bikinesi, L; Carmona, S; Dean, N; Fisher-Walker, CL; Hamunime, N; Hong, SY; Hunter, CJ; Jordan, MR; Kana, V; Mutenda, N; Negussie, T; Parkin, N; Raizes, EG; Sawadogo, S; Shiningavamwe, AN; Steegen, K; Tang, AM; Yang, C | 1 |
| Benson, CA; Cardoso, SW; Fletcher, CV; Ive, P; Kendall, MA; Lalloo, U; Podany, AT; Wu, X | 1 |
| Cassim, H; Gray, GE; Greeff, OBW; Lazarus, E; Liberty, A; Otwombe, K; Violari, A | 1 |
| Achan, J; Bangirana, P; Banik, A; Boivin, MJ; Giron, LB; Pillai, SK; Ruel, TD; Sikorskii, A | 1 |
| de Mast, Q; Kinabo, GD; Mchaile, DN; Schellekens, AFA; Van de Wijer, L; van der Ven, AJAM | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Mbete, N; Murnane, PM; Patel, F; Shiau, S; Strehlau, R | 1 |
| Hill, AM; Venter, F | 1 |
| de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J | 1 |
| Tartaglia, A | 1 |
| Dalal, V; Murthy, AN; Ravi, PR; Vats, R | 1 |
| Fairlie, L; Meyers, T; Moultrie, H; Pinillos, F; Sawry, S; van Zyl, G; Wong, JY | 1 |
| Ajose, O; Beanland, RL; Calmy, A; Doherty, M; Ford, N; Irvine, C; Mayer, KH; Rapparini, C; Shubber, Z; Vitoria, M | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; Celesia, BM; Cozzi-Lepri, A; d'Arminio Monforte, A; De Luca, A; Galli, M; Gianotti, N; Mussini, C; Pinnetti, C; Spagnuolo, V | 1 |
| Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fortuin-de Smidt, M; Igumbor, EU; Maartens, G; Stinson, K; Technau, KG | 1 |
| Ananworanich, J; Boonrak, P; Bunupuradah, T; Burger, D; Engchanil, C; Intasan, J; Kosalaraksa, P; Lumbiganon, P; Ruxrungtham, K; Schutz, M | 1 |
| Cohen, C; De Luca, A; Grant, P; Harrington, R; Hawkins, T; Kempf, D; Nadler, J; Rode, R; Shafer, R; Wong, EC; Zolopa, A | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| García Deltoro, M | 1 |
| Arranz Caso, JA | 1 |
| López Aldeguer, J | 1 |
| Bierman, WF; Boucher, CA; de Jong, D; Fun, A; Jaspers, CA; Kagan, R; Nijhuis, M; Schurink, KA; van Agtmael, MA; Wensing, AM | 1 |
| Aberg, J; Andrade, A; Dehlinger, M; Eshleman, SH; Ferguson, E; Flexner, C; Gross, R; Kashuba, A; Kmack, A; Lalama, C; Mildvan, D; Parsons, T; Rosenkranz, SL; Sanne, I; Tierney, C | 1 |
| Abrams, EJ; Coovadia, A; Ko, S; Kuhn, L; Meyers, T; Reitz, C; Sherman, G; Strehlau, R | 1 |
| Calza, L; Colangeli, V; Erario, A; Grossi, G; Manfredi, R; Mosca, L; Piergentili, B; Pocaterra, D; Verucchi, G; Viale, P | 1 |
| Dhlomo, S; Emery, S; Grandits, G; Khabo, P; Khanyile, T; Komati, S; Magongoa, D; Naidoo, LC; Neaton, JD; Polis, M; Qolohle, D; Ratsela, A | 1 |
| Bruce-Keller, AJ; Domingue, M; Gupta, S; Ingram, DK; Keller, JN; Kheterpal, I; Knight, AG; Pistell, PJ; Ruiz, C; Uranga, RM | 1 |
| Doroshyenko, O; Fätkenheuer, G; Frank, D; Fuhr, U; Hein, W; Jetter, A; Kirchheiner, J; Klaassen, T; Schömig, E; Seeringer, A; Wyen, C | 1 |
| Acosta, EP; Easley, KA; Eaton, ME; Lennox, JL; Long, MC; Masalovich, SE; Ofotokun, I; Ritchie, JC | 1 |
| Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H | 1 |
| Cotton, M; Eley, B; Fairlie, L; Maartens, G; McIlleron, H; Merry, C; Meyers, T; Nuttall, J; Rabie, H; Ren, Y; Smith, PJ | 1 |
| Kuhn, L; Meyers, TM; Moultrie, H; Yotebieng, M | 1 |
| Cozzi-Lepri, A; Dunn, D; Kjær, J; Lundgren, JD; Paredes, R; Phillips, AN; Pillay, D; Prosperi, MC; Sabin, CA | 1 |
| Bergin, C; Hennessy, M; Hopkins, S; Kennedy, A; Mulcahy, F; Spiers, JP | 1 |
| Allan, S; Back, D; Fidler, S; Fisher, M; Gilleran, G; Heald, L; Jayasuriya, A; Owen, A; Smit, E; Taylor, S; Wilkins, E | 1 |
| Asboe, D; Bansi, L; Barber, TJ; Dunn, D; Gilson, R; Harrison, L; Kirk, S; Pillay, D; Williams, I | 1 |
| Clotet, B; Domingo, P; Galindo, MJ; Imaz, A; Iribarren, JA; Llibre, JM; Mariño, A; Miralles, C; Moreno, S; Ornelas, A; Santos, JR; Schapiro, JM | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Kaleebu, P; Kasirye, R; Kikaire, B; Mambule, I; Musana, H; Pillay, D; Reid, A; Robertson, V; Spyer, M; Ssali, F; Walker, AS; Yirrell, D | 1 |
| Abel, F; Behrens, G; Domingo, P; Maserati, R; Pearce, G; Rieger, A; Wang, H | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Ananworanich, J; Bunupuradah, T; Chobkarjing, U; Chuanjaroen, T; Kosalaraksa, P; Lumbiganon, P; Pancharoen, C; Phanuphak, P; Pinyakorn, S; Puthanakit, T | 1 |
| Bierhoff, M; Boucher, CA; Fibriani, A; Ten Kate, RW | 1 |
| Bernstein, B; Brun, SC; Isaacson, JD; Kempf, DJ; King, MS; Richards, B; Rode, R; Sun, E; Sylte, J | 1 |
| Korn, K; Moschik, G; Paatz, C; Schmidt, B; Schnell, T; Thein, C; Walter, H | 1 |
| Arroyo, JA; Baldovi, F; de Lazzari, E; Domingo, P; Galindo, MJ; Gatell, JM; Larrousse, M; León, A; Martínez, E; Milinkovic, A | 1 |
| Boeri, E; Castagna, A; Danise, A; Gianotti, N; Hasson, H; Lazzarin, A; Nozza, S; Seminari, E | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Badri, S; Conover, CS; Jacobson, LP; Li, X; Margolick, JB; Riddler, SA; Witt, MD | 1 |
| Adler, E; Cohen, C; Fessel, WJ; Gladysz, A; Gonzalez-Garcia, J; McGovern, R; McLaren, C; Nieto-Cisneros, L; Zala, C | 1 |
| Jäger, H; Theobald, T | 1 |
| Antoniadou, A; Giamarellou, H; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Poulakou, G; Tsiodras, S | 1 |
| Chan-Tack, KM; Edozien, A | 1 |
| Hussain, S; Khayat, A; Rathore, MH; Tolaymat, A | 1 |
| Hansen, AB; Justesen, US; Mathiesen, S; Von Lüttichau, HR | 1 |
| Babacan, E; Carlebach, A; Dauer, B; Gute, P; Haberl, A; Hermschulte, Y; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| Allavena, C; Brunet-François, C; Chêne, G; Cuzin, L; Dellamonica, P; Le Moing, V; Lewden, C; Masquelier, B; Raffi, F; Spire, B; Taieb, A | 1 |
| Agarwal, R; Considine, RV; Dubé, MP; Gupta, SK; Mather, KJ; Saha, CK | 1 |
| Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D | 1 |
| Egbers, C; Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ | 1 |
| Arranz, A; Arribas, JR; Delgado, R; González-García, J; Hernando, A; Miralles, P; Pérez-Valero, I; Pulido, F | 1 |
| Geretti, AM | 1 |
| Mascolini, M | 1 |
| Han, L; Hsu, A; Kempf, DJ; Lin, CT; Mo, H; Molla, A; Vasavanonda, S | 1 |
Reviews
7 review(s) available for lopinavir and HIV
| Article | Year |
|---|---|
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Emtricitabine; HIV; HIV Infections; Humans; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Tenofovir; World Health Organization | 2015 |
[Resistance to darunavir].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Male; Multicenter Studies as Topic; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Phenotype; Point Mutation; Pyridazines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
[Monotherapy in treatment-naïve patients].
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load; Virus Replication | 2008 |
[Lopinavir/ritonavir monotherapy. Possible indications].
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Mitochondria; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load; Virus Replication | 2008 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Resistance testing methodologies and mechanisms of resistance.
Topics: Adenine; Anti-HIV Agents; CCR5 Receptor Antagonists; Drug Resistance, Viral; HIV; Humans; Lopinavir; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Pyrimidinones; Tenofovir | 2007 |
Trials
16 trial(s) available for lopinavir and HIV
| Article | Year |
|---|---|
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Topics: Adult; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Rifabutin; Rifampin; Ritonavir; Tuberculosis | 2021 |
Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Lopinavir; Male; Neurocognitive Disorders; Reverse Transcriptase Inhibitors; Uganda | 2017 |
Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Topics: Anti-HIV Agents; Blood Chemical Analysis; CD4 Lymphocyte Count; Child; Cholesterol; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; Saquinavir; Thailand; Treatment Refusal; Triglycerides; Viral Load | 2008 |
[Darunavir as first-line therapy. The TITAN study].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Darunavir; Diarrhea; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Lopinavir; Male; Prognosis; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Sulfonamides | 2008 |
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.
Topics: Anti-Retroviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Proportional Hazards Models; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Child, Preschool; Drug Therapy, Combination; Ethionamide; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Isoniazid; Kaplan-Meier Estimate; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; RNA, Viral; South Africa; Tuberculosis, Pulmonary; Viral Load | 2010 |
A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; RNA, Viral; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2010 |
Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.
Topics: Adult; Anti-HIV Agents; Area Under Curve; CD4-Positive T-Lymphocytes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Orosomucoid; Prospective Studies; Protein Binding; Ritonavir; RNA, Viral | 2011 |
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Topics: Adult; Africa; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 2012 |
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV; HIV Infections; Humans; Lamivudine; Lipids; Lopinavir; Male; Medication Adherence; Middle Aged; Organophosphorus Compounds; Ritonavir; Treatment Outcome | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Topics: Drug Resistance, Viral; Drug Therapy, Combination; Genes, Viral; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Logistic Models; Lopinavir; Mutation; Phenotype; Pyrimidinones; Ritonavir; RNA, Viral; Time Factors; Viral Load | 2002 |
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Cholesterol, LDL; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides | 2005 |
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
Topics: Adult; Aged; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Salvage Therapy; Saquinavir; Viral Load | 2006 |
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load | 2007 |
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Topics: Adult; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Longitudinal Studies; Lopinavir; Male; Mutation; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
Other Studies
53 other study(ies) available for lopinavir and HIV
| Article | Year |
|---|---|
Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir).
Topics: Anti-HIV Agents; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; HIV; HIV Protease Inhibitors; Humans; Lopinavir; Microbial Sensitivity Tests; Mixed Function Oxygenases; Pyrimidinones | 2001 |
Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Topics: Animals; Anti-HIV Agents; Dogs; Drug Resistance, Multiple, Viral; HIV; HIV Protease Inhibitors; Inhibitory Concentration 50; Mutation; Rats; Structure-Activity Relationship; Virus Replication | 2005 |
Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.
Topics: Alkanes; Binding Sites; Catalytic Domain; Computer Simulation; Genotype; HIV; HIV Protease; HIV Protease Inhibitors; Humans; South Africa | 2011 |
Osteonecrosis of the humeral head in a human immunodeficiency virus-infected patient under tenofovir disoproxil fumarate-emtricitabine-lopinavir/ritonavir for 10 years: a case report.
Topics: Emtricitabine; Female; HIV; HIV Infections; Humans; Humeral Head; Lopinavir; Middle Aged; Osteonecrosis; Ritonavir; Tenofovir | 2021 |
A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
Topics: Anti-Retroviral Agents; HIV; HIV Infections; Humans; Latent Tuberculosis; Lopinavir; Models, Biological; Rifampin; Ritonavir; Tuberculosis | 2022 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis | 2023 |
Cryptococcal meningitis and immune reconstitution inflammatory syndrome in a pediatric patient with HIV after switching to second line antiretroviral therapy: a case report.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Antigens, Fungal; Benzoxazines; Child; Cryptococcus neoformans; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fluconazole; HIV; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Lopinavir; Meningitis, Cryptococcal; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2020 |
Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Topics: Anti-HIV Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Testing; Diabetes Mellitus, Type 2; Drug Combinations; gamma-Globulins; HIV; HIV Infections; Humans; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
FGF21 and its Relationship with Inflammatory and Metabolic Parameters in HIV Patients after Antiretroviral Treatment.
Topics: Adult; Anti-Retroviral Agents; Atherosclerosis; Female; Fibroblast Growth Factors; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Inflammation Mediators; Lipid Metabolism; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Risk Factors; Ritonavir; Tenofovir; Young Adult | 2020 |
High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Namibia; Prevalence; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Young Adult | 2020 |
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Topics: Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Retrospective Studies; Ritonavir; South Africa; Stavudine; Treatment Outcome; Viral Load | 2017 |
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous System.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nervous System; Nevirapine; Ritonavir | 2018 |
Reply to Van de Wijer et al.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nevirapine; Ritonavir | 2018 |
The unexpected success of NRTIs in second-line treatment.
Topics: Anti-HIV Agents; DNA-Directed RNA Polymerases; Follow-Up Studies; HIV; Lopinavir; Raltegravir Potassium; Reverse Transcriptase Inhibitors | 2018 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug Interactions; Ethambutol; Female; HIV; HIV Infections; Humans; Isoniazid; Lopinavir; Male; Models, Statistical; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.
Topics: Animals; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Drug Stability; Endocytosis; HIV; HIV Protease Inhibitors; Humans; Intestinal Absorption; Lipids; Lopinavir; Male; Nanoparticles; Rats, Wistar; Ritonavir; Stearic Acids; Tissue Distribution | 2014 |
Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Humans; Infant; Lopinavir; Male; Mutation, Missense; Ritonavir; South Africa; Treatment Failure; Viral Load | 2015 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; RNA, Viral; Viral Load; Viremia; Young Adult | 2017 |
First-line antiretroviral drug discontinuations in children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; South Africa; Stavudine; Withholding Treatment; Zidovudine | 2017 |
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
Topics: Adolescent; Adult; Aged; Cohort Studies; Drug Resistance, Viral; Female; Genes, Viral; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; Young Adult | 2008 |
Two studies show Kaletra and Isentress similarly suppress HIV, yet have different side effects.
Topics: CD4 Lymphocyte Count; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2009 |
Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; DNA Mutational Analysis; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; HIV; HIV Infections; HIV Protease; Humans; Longitudinal Studies; Lopinavir; Molecular Sequence Data; Mutation, Missense; Phylogeny; Pyrimidinones; Ritonavir; Sequence Analysis, DNA; Sequence Homology; Treatment Failure; Virus Replication | 2009 |
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.
Topics: Adult; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Viral Load | 2011 |
Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice.
Topics: Animals; Cognition; Drug Administration Schedule; Drug Combinations; HIV; HIV Infections; HIV Protease Inhibitors; Lopinavir; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Motor Activity; Pyrimidinones; Ritonavir; Weight Loss | 2010 |
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Digoxin; Down-Regulation; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Middle Aged; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Clinical Trials, Phase II as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pyrimidinones; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; RNA, Viral; South Africa; Young Adult | 2011 |
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child, Preschool; Drug Interactions; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infant; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; South Africa; Treatment Outcome; Tuberculosis | 2011 |
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Coinfection; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Hospitals, Public; Humans; Infant; Lopinavir; Male; Mycobacterium tuberculosis; Recurrence; Ritonavir; South Africa; Survival Analysis; Tuberculosis, Pulmonary; Viral Load | 2011 |
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.
Topics: Cohort Studies; Data Interpretation, Statistical; Drug Resistance, Viral; Genotype; Health Personnel; HIV; HIV Infections; Humans; Internet; Linear Models; Lopinavir; Mutation | 2011 |
Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Cell Line; Cohort Studies; Coinfection; Female; Hepacivirus; Hepatic Stellate Cells; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Ireland; Lopinavir; Male; Monocytes; Recombinant Proteins; Ribavirin; RNA, Viral; Saquinavir; Tissue Inhibitor of Metalloproteinase-2; United Kingdom; Viral Load | 2011 |
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Plasma; Ritonavir; Time Factors; Treatment Outcome; Viral Load | 2012 |
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Ritonavir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Treatment Failure; United Kingdom; Young Adult | 2012 |
Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Cohort Studies; Female; HIV; HIV Infections; HIV Protease; Humans; Lopinavir; Male; Mutation, Missense; Retrospective Studies; Ritonavir; Treatment Failure; United States | 2012 |
Long-term lopinavir/ritonavir monotherapy in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Child; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Ritonavir; Time Factors; Treatment Outcome; Viral Load | 2013 |
Ongoing HIV replication in cerebrospinal fluid under successful monotherapy.
Topics: Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Viral Load; Virus Replication | 2013 |
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Sulfonamides | 2003 |
Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cholesterol; Cholesterol, HDL; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Diseases; Pyrimidinones; Risk Factors; Ritonavir; Triglycerides | 2004 |
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides | 2004 |
Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.
Topics: Adult; Age Factors; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Depression; Dideoxynucleosides; Ethnicity; HIV; HIV Infections; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Pyrimidinones; Risk Factors; RNA, Viral; Treatment Refusal | 2005 |
[First-line monotherapy with boostered protease inhibitor. Effectively reduce viral load with only one drug?].
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Early Diagnosis; HIV; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Lopinavir; Pyrimidinones; Treatment Outcome; Viral Load | 2005 |
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides; Viral Load | 2006 |
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression.
Topics: Anti-HIV Agents; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Viral Load | 2006 |
Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.
Topics: Adenine; Anti-HIV Agents; Child; Diabetes Insipidus, Nephrogenic; Didanosine; Drug Therapy, Combination; Fanconi Syndrome; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Lopinavir; Organophosphonates; Pregnancy; Pregnancy Complications; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Genotype; HIV; HIV Infections; Humans; Lopinavir; Male; Oxazines; Oxidoreductases, N-Demethylating; Pyrimidinones | 2006 |
XVI International AIDS Conference: Part 2.
Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides | 2006 |
[Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
Topics: Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Tolerance; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pilot Projects; Pyrimidinones; Ritonavir; Treatment Failure | 2007 |
Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study.
Topics: Adult; Aged; Cross-Sectional Studies; Endothelium, Vascular; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nitroglycerin; Pilot Projects; Proteinuria; Pyrimidinones; Regional Blood Flow; Ritonavir; Vasodilation | 2007 |
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
Topics: Antibiotics, Antitubercular; Child, Preschool; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; Tuberculosis | 2008 |
ICAAC eyes PIs, NNRTIs, and STIs.
Topics: Animals; Anti-HIV Agents; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Mutation; Ontario; Pyrimidinones; Reverse Transcriptase Inhibitors; Viral Load | 2000 |
[No resistance even after 1 year. New drug combination against HIV].
Topics: Drug Combinations; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome | 2001 |
In vitro antiviral interaction of lopinavir with other protease inhibitors.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Lopinavir; Microbial Sensitivity Tests; Pyrimidinones | 2002 |